Tags

Type your tag names separated by a space and hit enter

Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease.
Clin Biochem. 2015 Dec; 48(18):1246-51.CB

Abstract

OBJECTIVES

Decreased concentration of menaquinone-4 (MK-4) seems to be an important risk factor of vascular calcification in haemodialysis (HD) patients. Optimal dietary intake, as well as serum MK-4 reference range, in HD has not been determined, yet. The aim of the present study was to assess daily vitamin K1 and MK-4 intakes and their relation to serum MK-4 concentration in HD patients.

DESIGN AND METHODS

Daily vitamin K1 and MK-4, micro- and macronutrients and energy intakes were assessed using 3-day food diary completed by patients and serum MK-4 concentration was measured by HPLC [limit of quantification (LOQ): 0.055 ng/mL] in 85 HD patients (51 males) and 22 apparently healthy subjects.

RESULTS

Daily MK-4 intake was significantly lower (by 29%) among HD, while K1 consumption was similar in both groups. Daily MK-4 intake was associated with fat and protein consumption in HD (r=0.43, p<0.001 and r=0.33, p=0.004, respectively). In HD serum MK-4 concentration was more frequently below LOQ (in 41% HD and 5% controls, p<0.001) and in those HD with quantifiable values was lower than in the controls (by 42%). The correlations between MK-4 concentrations and both MK-4 and K1 daily intakes were weaker in HD (r=0.38 and r=0.30 respectively) than in the control group (r=0.47 and r=0.45, respectively). In multiple regression analysis the variability of serum MK-4 concentrations in HD patients was explained by its daily intake.

CONCLUSIONS

Decreased serum MK-4 concentration in HD patients is caused by lower dietary MK-4 intake, mainly due to diminished meat consumption, and in addition, probably reduced K1 conversion.

Authors+Show Affiliations

Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland; Department of Nephrology, Transplantation and Internal Medicine, Medical Faculty in Katowice, Medical University of Silesia, Francuska 20-24, 40-027 Katowice, Poland.Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.Department of Internal Medicine and Clinical Pharmacology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland.Department of Internal Medicine and Clinical Pharmacology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland.Department of Nephrology, Transplantation and Internal Medicine, Medical Faculty in Katowice, Medical University of Silesia, Francuska 20-24, 40-027 Katowice, Poland.Dialysis Center in Tarnowskie Góry, Fresenius Nephrocare, Pyskowicka 47, 42-612 Tarnowskie Góry, Poland.Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.Department of Internal Medicine and Clinical Pharmacology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland.Department of Nephrology, Transplantation and Internal Medicine, Medical Faculty in Katowice, Medical University of Silesia, Francuska 20-24, 40-027 Katowice, Poland.Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland. Electronic address: chj@poczta.fm.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26282719

Citation

Wyskida, Katarzyna, et al. "Daily Intake and Serum Concentration of Menaquinone-4 (MK-4) in Haemodialysis Patients With Chronic Kidney Disease." Clinical Biochemistry, vol. 48, no. 18, 2015, pp. 1246-51.
Wyskida K, Żak-Gołąb A, Łabuzek K, et al. Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. Clin Biochem. 2015;48(18):1246-51.
Wyskida, K., Żak-Gołąb, A., Łabuzek, K., Suchy, D., Ficek, R., Pośpiech, K., Olszanecka-Glinianowicz, M., Okopień, B., Więcek, A., & Chudek, J. (2015). Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. Clinical Biochemistry, 48(18), 1246-51. https://doi.org/10.1016/j.clinbiochem.2015.08.011
Wyskida K, et al. Daily Intake and Serum Concentration of Menaquinone-4 (MK-4) in Haemodialysis Patients With Chronic Kidney Disease. Clin Biochem. 2015;48(18):1246-51. PubMed PMID: 26282719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. AU - Wyskida,Katarzyna, AU - Żak-Gołąb,Agnieszka, AU - Łabuzek,Krzysztof, AU - Suchy,Dariusz, AU - Ficek,Rafał, AU - Pośpiech,Kornel, AU - Olszanecka-Glinianowicz,Magdalena, AU - Okopień,Bogusław, AU - Więcek,Andrzej, AU - Chudek,Jerzy, Y1 - 2015/08/15/ PY - 2015/04/24/received PY - 2015/07/04/revised PY - 2015/08/12/accepted PY - 2015/8/19/entrez PY - 2015/8/19/pubmed PY - 2016/9/14/medline KW - Chronic kidney disease KW - Haemodialysis KW - Menaquinone-4 KW - Phylloquinone KW - Vitamin K intake SP - 1246 EP - 51 JF - Clinical biochemistry JO - Clin Biochem VL - 48 IS - 18 N2 - OBJECTIVES: Decreased concentration of menaquinone-4 (MK-4) seems to be an important risk factor of vascular calcification in haemodialysis (HD) patients. Optimal dietary intake, as well as serum MK-4 reference range, in HD has not been determined, yet. The aim of the present study was to assess daily vitamin K1 and MK-4 intakes and their relation to serum MK-4 concentration in HD patients. DESIGN AND METHODS: Daily vitamin K1 and MK-4, micro- and macronutrients and energy intakes were assessed using 3-day food diary completed by patients and serum MK-4 concentration was measured by HPLC [limit of quantification (LOQ): 0.055 ng/mL] in 85 HD patients (51 males) and 22 apparently healthy subjects. RESULTS: Daily MK-4 intake was significantly lower (by 29%) among HD, while K1 consumption was similar in both groups. Daily MK-4 intake was associated with fat and protein consumption in HD (r=0.43, p<0.001 and r=0.33, p=0.004, respectively). In HD serum MK-4 concentration was more frequently below LOQ (in 41% HD and 5% controls, p<0.001) and in those HD with quantifiable values was lower than in the controls (by 42%). The correlations between MK-4 concentrations and both MK-4 and K1 daily intakes were weaker in HD (r=0.38 and r=0.30 respectively) than in the control group (r=0.47 and r=0.45, respectively). In multiple regression analysis the variability of serum MK-4 concentrations in HD patients was explained by its daily intake. CONCLUSIONS: Decreased serum MK-4 concentration in HD patients is caused by lower dietary MK-4 intake, mainly due to diminished meat consumption, and in addition, probably reduced K1 conversion. SN - 1873-2933 UR - https://www.unboundmedicine.com/medline/citation/26282719/Daily_intake_and_serum_concentration_of_menaquinone_4__MK_4__in_haemodialysis_patients_with_chronic_kidney_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(15)00391-4 DB - PRIME DP - Unbound Medicine ER -